Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The DNA Company Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution profile is characterized by its simplicity, with only 1 distinct examiner and 1 distinct art unit involved. This indicates that the current patent filings are concentrated within a specific technical niche that does not span multiple examination groups at the patent office.
The busiest examiner, BAILEY, STEVEN WILLIAM, is currently handling 1 busiest examiner pending office action. This represents the only active prosecution for the company, placing significant importance on the examiner's specific feedback and requirements. Because the portfolio only interacts with 1 distinct art unit, the administrative burden is low, and the legal strategy can be tailored specifically to the standards of that unit.
The success of the company's current patent efforts rests on the resolution of the 1 pending office action under the guidance of BAILEY, STEVEN WILLIAM. Practitioners should focus on the examiner's specific technical background within Biotechnology & Pharmaceuticals to craft more persuasive responses. By addressing the 1 pending office action with a clear understanding of the 1 distinct art unit's expectations, the company can more efficiently navigate the prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAILEY, STEVEN WILLIAM | 1 | 31.6% | +15.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17245300 | SYSTEMS AND METHODS FOR PERFORMING A GENOTYPE-BASED ANALYSIS OF AN INDIVIDUAL | BAILEY, STEVEN WILLIAM | 146d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17245300 | SYSTEMS AND METHODS FOR PERFORMING A GENOTYPE-BASED ANALYSIS OF AN INDIVIDUAL | BAILEY, STEVEN WILLIAM | 146d overdue |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17245300 | SYSTEMS AND METHODS FOR PERFORMING A GENOTYPE-BASED ANALYSIS OF AN INDIVIDUAL | BAILEY, STEVEN WILLIAM | 1687 | §101§103§112 | Final Rejection | 146d overdue | Pending | Apr 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe DNA Company Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Steven William Bailey has the most, with 1 of The DNA Company Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.